Company intelligence / Profile preview

Amplo

Towson, Maryland, United States

Ownership: Private
Employees: ~3
Development stage: Other

Overview

Late-stage preclinical AAV gene therapies showing efficacy in mouse models for Dok-7 and ColQ CMS, with GLP toxicology demonstrating safety; advancing toward IND for AMP-101.

Therapeutic areas: NeurologyRare Diseases
Modalities: Gene therapy
Industry: Biotech

Partnerships

Andelyn Biosciences (CDMO for AAV manufacturing)

Beyond the preview

Go deeper on Amplo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amplo.

Explore the full profile